VivoSeq
Other

SGLT-2 Inhibitor

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

SGLT-2 Inhibitor is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Completed3 · 60%
Not yet recruiting1 · 20%
Unknown status1 · 20%

Clinical Trials

Trial Activity

SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.
Completed·UUniversity of Leicester·Phase 4·NCT02798744·68 enrolled
SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF
Not yet recruiting·UUniversity of Palermo·Phase 4·NCT06442280·544 enrolled
The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.
Unknown status·—·N/A·NCT05333159·1,424 enrolled
Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists
Completed·UUniversity of Padova·N/A·NCT04184947·10,000 enrolled
Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?
Completed·SSadat City University·N/A·NCT05359341·175 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)